Becton, Dickinson and Company

BDX

NYSE

193.96

USD

+0.20(+0.10%)

As of today

Overview Financials Dividends Ratios Discussions Analysis

Becton, Dickinson and Company fundamentals

Overview Income Statement Balance Sheet Cash Flow

Key ratios

P/E Ratio

33.33

Price/Book

2.19

Debt/Equity

75.55%

Return on Equity

6.63%

Dividend Yield

2.14%

EBITDA

4.96B

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Statements Highlights

AnnualQuarterly

Period Ending	Sep 30, 2021	Sep 30, 2022	Sep 30, 2023	Sep 30, 2024	Sep 30, 2025
Total Revenue	19,131,000,000	18,870,000,000	19,372,000,000	20,178,000,000	21,839,000,000
Gross Profit	8,631,000,000	8,477,000,000	8,170,000,000	9,125,000,000	9,924,000,000
Operating Income	2,250,000,000	2,282,000,000	2,111,000,000	2,397,000,000	2,578,000,000
Net Income	2,092,000,000	1,779,000,000	1,484,000,000	1,705,000,000	1,678,000,000
Total Assets	53,880,000,000	52,934,000,000	52,780,000,000	57,286,000,000	55,325,000,000
Total Current Liabilities	6,626,000,000	7,811,000,000	6,641,000,000	8,956,000,000	8,313,000,000
Total Equity	23,677,000,000	25,282,000,000	25,797,000,000	25,889,000,000	25,390,000,000
Free Cash Flow	3,416,000,000	1,660,000,000	2,115,000,000	3,072,000,000	2,670,000,000
Cash from Operations	4,647,000,000	2,633,000,000	2,989,000,000	3,798,000,000	3,430,000,000
Cash from Investing	-1,880,000,000	-3,231,000,000	-716,000,000	-5,514,000,000	-818,000,000
Cash from Financing	-3,306,000,000	-591,000,000	-1,957,000,000	2,087,000,000	-3,617,000,000
Net Change in Cash	-525,000,000	-1,233,000,000	322,000,000	375,000,000	-1,005,000,000

Becton, Dickinson and Company

BDX

193.96

Becton, Dickinson and Company fundamentals

Key ratios

Statements Highlights

Dividends

Analyst Recomendations